Compounded GLP-1 Legal Status 2026: What the FDA's Proposal Really Means

If you've been getting compounded semaglutide or tirzepatide through a telehealth provider and you're wondering whether it's still legal, you're not alone — and the honest answer is more nuanced than most headlines suggest. Mass compounding of these drugs already wound down in 2025 once the FDA declared the underlying shortages over. Now, in 2026, the FDA has taken a further step: a formal proposal, published May 1, 2026, to permanently exclude semaglutide, tirzepatide, and liraglutide from the list of substances outsourcing pharmacies are allowed to compound from bulk ingredients (National Law Review, July 10, 2026).

That proposal's public comment period closed June 30, 2026 — but as of this writing, it is still pending, not finalized, and not yet in effect. Here's what actually changed, what's still allowed, and what your real options are if you're currently using a compounded GLP-1.

First, the Legal Basics: 503A vs. 503B

Compounding pharmacies in the US operate under one of two very different legal frameworks, and the FDA's 2026 proposal only touches one of them.

503B Outsourcing Facilities

These are large-scale compounding operations that can produce bulk quantities, often for telehealth companies distributing nationwide. Under Section 503B of the Food, Drug and Cosmetic Act, a 503B facility generally cannot compound a drug using a bulk substance unless that substance appears on the FDA's "503B Bulks List" (meaning FDA has found a clinical need for it), or the drug is currently on FDA's official drug shortage list (National Law Review). This is the pathway the FDA's May 2026 proposal targets.

503A State-Licensed Pharmacies

These are traditional, smaller-scale compounding pharmacies, typically tied to a specific prescription for a specific patient. The FDA's 503B proposal does not affect 503A pharmacies at all — they remain permitted, subject to their own separate rules, to compound with active ingredients found in FDA-approved drugs when there's a genuine, documented, patient-specific need (National Law Review).

What Actually Happened, Timeline by Timeline

2022–2024: Shortage-Based Compounding

When branded tirzepatide and semaglutide products were in short supply, both 503A and 503B pharmacies were legally permitted to compound versions of these drugs to fill the gap.

December 2024 – February 2025: Shortages Declared Over

FDA removed tirzepatide from the drug shortage list in December 2024, and semaglutide in February 2025. Once a shortage ends, the legal basis for shortage-based compounding of that drug ends too, on a set wind-down timeline.

April 30, 2026: The New Proposal

FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely — meaning 503B outsourcing facilities would have no remaining legal pathway to compound these three drugs from bulk substances once the shortages are over and the rule is finalized. FDA Commissioner Marty Makary said: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," adding that the action reflects the agency's responsibility "to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input" (National Law Review).

May 1, 2026: Federal Register Publication

The proposal was formally published as a Federal Register notice — "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act," 91 Fed. Reg. 23431. In it, FDA stated it had "not identified a basis to conclude" that the approved semaglutide and tirzepatide products are medically unsuitable for certain patients in a way that would justify a compounded alternative (National Law Review).

June 30, 2026: Comment Period Closed

The public comment window closed on this date. Late comments were not accepted. The rule is still pending FDA review as of this writing — it has not been finalized.

Why Liraglutide Is Different Right Now

Unlike semaglutide and tirzepatide, liraglutide injection currently remains on FDA's drug shortage list. That means, despite being named in the same proposal, 503B outsourcing facilities can still legally compound liraglutide right now under the shortage exception — a detail that's easy to miss if you only read the headlines (National Law Review).

The Narrow Door That's Still Open

Even if the 503B proposal is finalized exactly as written, one legal compounding pathway survives: a state-licensed 503A pharmacy can still compound a genuinely personalized, non-copy formulation for an individual patient — but only when a prescriber documents a real, clinically significant reason that specific patient needs something different from the FDA-approved product (for example, a documented allergy to an inactive ingredient). FDA has also indicated it generally won't pursue 503A pharmacies filling four or fewer units of a given compounded product per month (Weight Loss Rankings, July 11, 2026).

What doesn't qualify: blanket "weight-loss plus B12" combination products marketed to broad patient populations without individualized documentation. FDA has separately clarified conditions under which it will treat certain compounded drug combinations — including GLP-1s combined with vitamin B12 outside specific parameters — as "essentially a copy" of an approved product, which is not compoundable outside a shortage (National Law Review).

Your Four Real Options If You're Currently on a Compounded GLP-1

1. Switch to Brand-Name at Lower Direct-Pay Prices

Manufacturers have cut self-pay prices substantially in 2025–2026. Zepbound (tirzepatide) self-pay vials now run roughly $299–$449/month through LillyDirect, and Wegovy (semaglutide) runs around $499/month through NovoCare for some doses — a much narrower gap versus the roughly $1,300 retail list price than a year or two ago (Weight Loss Rankings).

2. Switch to an Oral Pill

Both major oral GLP-1 options — Foundayo (orforglipron), FDA-approved in April 2026, and the oral Wegovy pill — offer brand-adjacent, lower self-pay starting prices with none of the sourcing uncertainty of compounded products. See our Foundayo complete guide and oral Wegovy pill launch guide for full details on both.

3. Taper Off Under Medical Supervision

If cost or access makes continuing any GLP-1 impractical for you right now, a supervised taper is a legitimate option — just go in with realistic expectations about weight regain. Real-world data on what actually happens after stopping is more encouraging than older studies suggested; we cover that in detail separately.

4. What Not to Do

Buying "research peptides" from gray-market sources with no pharmacy oversight is not a safe substitute for any of the above — these products carry no quality, dosing, or sterility guarantees.

Where to Get a Legal Prescription Today

If you're weighing your options and want a licensed evaluation for brand-name or oral GLP-1 access, SkinnyRx via GLPTree connects patients with licensed telehealth providers offering legitimate prescription pathways — including guidance on financing for patients without full insurance coverage. For a full pricing comparison across every access route, see our GLP-1 cost guide.

Educational content only. Not medical or legal advice. Compounding regulations can change; confirm current status with your pharmacy, prescriber, or a licensed attorney before making treatment decisions.

Frequently Asked Questions

Is compounded semaglutide still legal in 2026?

It's complicated. Mass 503B compounding largely ended in 2025 once the drug shortages were declared over. A May 2026 FDA proposal would permanently close the remaining bulk-substance pathway for 503B facilities, but that proposal is still pending, not finalized. A narrow 503A personalized-compounding pathway remains available for documented, patient-specific clinical needs.

Has the FDA banned compounded GLP-1 drugs?

No. As of this writing, the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, but the proposal is pending review after its June 30, 2026 comment period closed — it is not a finalized ban.

What's the difference between a 503A and 503B compounding pharmacy?

503B outsourcing facilities compound at scale and are the target of the FDA's 2026 proposal. 503A pharmacies compound for individual patients under separate state-level rules and are not affected by the 503B proposal.

Is liraglutide compounding still allowed?

Yes, currently — liraglutide injection remains on the FDA's drug shortage list, so 503B facilities can still legally compound it under the shortage exception, despite being named in the same proposal targeting semaglutide and tirzepatide.

What should I do if my compounded GLP-1 becomes unavailable?

Talk to your prescriber about switching to brand-name tirzepatide or semaglutide at current direct-pay pricing, switching to an oral GLP-1 pill, or a supervised taper — all of which are covered in detail above.

Are compounded GLP-1s FDA-approved?

No. Compounded drugs are not FDA-approved products; they're prepared by pharmacies under separate legal compounding rules and don't go through the FDA's standard drug approval process for safety and efficacy.

Sources

1. National Law Review — FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List:natlawreview.com (July 10, 2026)
2. Weight Loss Rankings — Compounded GLP-1 Going Away? Your 2026 Options:weightlossrankings.org (July 11, 2026)
3. Federal Register, 91 Fed. Reg. 23431 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the FD&C Act (May 1, 2026)